Compare DLO & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | PBLS |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 2021 | 2026 |
| Metric | DLO | PBLS |
|---|---|---|
| Price | $14.38 | $35.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 405.2K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $26.98 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $25.56 |
| 52 Week High | $16.78 | $36.82 |
| Indicator | DLO | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 66.14 |
| Support Level | $13.11 | $26.42 |
| Resistance Level | $14.50 | N/A |
| Average True Range (ATR) | 0.49 | 2.44 |
| MACD | -0.12 | 0.32 |
| Stochastic Oscillator | 24.86 | 86.81 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.